GrowGeneration (NASDAQ:GRWG) Stock

GrowGeneration

GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.

GrowGeneration Corp

Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.20 by 65 percent. This is a 15.38 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $8.886 billion which missed the analyst consensus estimate of $9.130 billion by 2.67 percent. This is a 18.41 percent decrease over sales of $10.891 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Cenovus Energy Q2 EPS $0.33 Beats $0.20 Estimate, Sales $8.886B Miss $9.130B Estimate

Third Quarter 2025 Outlook
In the third quarter of 2025, the Company expects to generate revenue between $130.0 million and $138.0 million.
The Company expects third quarter 2025 diluted net income per share between $0.17 and $0.25, and non-GAAP diluted net income per share between $0.35 and $0.43.

Guidance

PRLB

Proto Labs Sees Q3 Adj EPS $0.35-$0.43 vs $0.37 Est; Sees Sales $130M-$138M vs $129.652M Est; Sees Q3 GAAP EPS $0.17-$0.25 vs $0.20 Est

SQNS

Sequans Communications Q2 Adj. EPADS $(0.32) Misses $(0.27) Estimate, Sales $8.14M Miss $8.50M Estimate

KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) narrows FY2025 Adj EPS guidance from $3.71-$3.95 to $3.78-$3.88 vs $3.82 analyst estimate. Lowers FY2025 sales outlook from $8.700 billion-$9.100 billion to $7.900 billion-$8.100 billion vs $8.577 billion estimate.

KBR Narrows FY2025 Adj EPS Guidance from $3.71-$3.95 to $3.78-$3.88 vs $3.82 Est; Lowers FY2025 Sales Guidance from $8.700B-$9.100B to $7.900B-$8.100B vs $8.577B Est

PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) affirms FY2025 Adj EPS guidance from $1.48-$1.52 to $1.48-$1.52 vs $1.50 analyst estimate..

PG&E Affirms FY2025 Adj EPS Guidance of $1.48-$1.52 vs $1.50 Est

PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) lowers FY2025 GAAP EPS guidance from $1.29-$1.35 to $1.26-$1.32 vs $1.43 analyst estimate..

PG&E Lowers FY2025 GAAP EPS Guidance from $1.29-$1.35 to $1.26-$1.32 vs $1.43 Est

2025&nbsp;OUTLOOK2
The Cigna Group's outlook2 for full year 2025 consolidated adjusted income from operations1,2 is at least $29.60 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2025 dividends.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">(dollars in millions, except where noted and per share amounts)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;2025 Consolidated Metrics</td>
<td colspan="1" rowspan="1">
Projection for Full Year Ending
December 31,&nbsp; 2025
</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Income from Operations, per share1,2</td>
<td colspan="1" rowspan="1">at least $29.60</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Evernorth Adjusted Income from Operations, Pre-Tax1,2</td>
<td colspan="1" rowspan="1">at least $7,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2</td>
<td colspan="1" rowspan="1">at least $4,125</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cigna Healthcare Medical Care Ratio2,4</td>
<td colspan="1" rowspan="1">83.2% to 84.2%</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Cigna Group Expects FY2025 Adjusted Earnings Of At Least $29.60 vs $29.68 Est

Alignment Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) witnessed a 23.08% surge in its stock price during premarket trading on Thursday, after the company&#8217;s second-quarter earnings beat market expectations.
Check out how <a href="https://www.benzinga.com/quote/ALHC">ALHC stock is trading here</a>.
What Happened: The California-based healthcare company reported a total revenue of $1 billion in the second quarter, with a health plan membership of 223,700 as of June 30.
John Kao, the founder and CEO of Alignment Healthcare, noted, "In today&#8217;s Medicare Advantage environment, Alignment Healthcare&#8217;s second quarter performance proves that strong financial results and high-quality care can go hand in hand – with the right model."
See Also: <a href="https://benzinga.com/markets/cryptocurrency/25/02/43723477/billionaire-peter-theil-backed-crypto-startup-plasma-raises-20m-to-develop-bitcoin-based-stablecoin-network">Billionaire Peter Thiel-Backed Crypto Startup Plasma Raises $20M To Develop Bitcoin-Based Stablecoin Network</a>
Following the announcement, the company&#8217;s stock price surged by 10.36% to $13 during regular trading hours on Wednesday. The stock surged 23.08% to $16 during premarket trading.
Why It Matters: Alignment Healthcare beat expectations for the second quarter, delivering stronger-than-anticipated results across membership, revenue, profit, and earnings.
The company added more health plan members, bringing the total to about 223,700 — nearly 28% more than a year ago — and pulled in over $1 billion in revenue, up 49%.
It also posted a solid adjusted gross profit of $135.2 million and adjusted EBITDA of $45.9 million. With the strong performance, Alignment raised its full-year forecast across all these key areas.
This strong performance also follows the company&#8217;s recent decision to raise its full-year sales guidance from $3.77 billion-$3.81 billion to $3.8 billion-$3.91 billion, surpassing the $3.80&nbsp; billion estimate.&nbsp;
Benzinga's Edge Stock Rankings indicate ALHC stock has a positive trend across all time frames.  Here is <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how the stock fares</a> on other parameters.
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="466" height="114" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31053402/Screenshot-2025-07-30-084321-2.png" alt="" class="wp-image-1008710" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31053402/Screenshot-2025-07-30-084321-2.png 466w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31053402/Screenshot-2025-07-30-084321-2-300x73.png 300w" sizes="(max-width: 466px) 100vw, 466px" /></figure>
<ul class="wp-block-list">
<li>Read Next: <a href="https://benzinga.com/markets/macro-economic-events/25/07/46745168/trump-leaves-good-friend-india-in-the-cold-strikes-trade-deal-with-arch-rival-pakis">Trump Leaves &#8216;Good Friend&#8217; India In The Cold, Strikes Trade Deal With Arch Rival Pakistan Over &#8216;Massive Oil Reserves&#8217;</a></li>
</ul>
Photo:&nbsp;
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: khunkornStudio via Shutterstock

Equities

Markets

ALHC

Alignment Healthcare Surges Over 23% After Strong Q2 Performance

Aurinia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) raises FY2025 sales outlook from $250.00 million-$260.00 million to $260.00 million-$270.00 million vs $258.52 million estimate.

AUPH

Aurinia Pharmaceuticals Raises FY2025 Sales Guidance from $250.00M-$260.00M to $260.00M-$270.00M vs $258.52M Est

Genesis Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEL#NYSE">GEL</a>) reported quarterly losses of $(0.12) per share. This is a 52 percent increase over losses of $(0.25) per share from the same period last year. The company reported $377.348 million in sales this quarter. This is a 12.28 percent decrease over sales of $430.179 million the same period last year.

Genesis Energy Q2 EPS $(0.12) Up From $(0.25) YoY, Sales $377.348M Down From $430.179M YoY

Air Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) is looking for Q4 Adj EPS of $3.27-$3.47 vs $3.48 analyst estimate..

Air Products Sees Q4 Adj EPS $3.27-$3.47 vs $3.48 Est

KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.90 by 1.34 percent. This is a 9.64 percent increase over earnings of $0.83 per share from the same period last year. The company reported quarterly sales of $1.952 billion which missed the analyst consensus estimate of $2.081 billion by 6.20 percent. This is a 5.23 percent increase over sales of $1.855 billion the same period last year.

KBR Q2 Adj. EPS $0.91 Beats $0.90 Estimate, Sales $1.952B Miss $2.081B Estimate

&nbsp;Jamie Dimon, the CEO of&nbsp;JPMorgan Chase &amp; Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), has&nbsp;reportedly visited the White House twice&nbsp;in the past two months. This marks a significant shift in the relationship between the head of the largest American bank and President&nbsp;Donald Trump.
<h3 class="wp-block-heading">Dimon And Trump Discuss Economy, Housing And Interest Rates In Oval Office Meeting</h3>
Dimon met with Trump in the Oval Office last week to discuss the economy, trade, and financial regulation. Also present at the meeting were Treasury Secretary Scott Bessent and Commerce Secretary Howard Lutnick. The conversation touched on topics such as the ongoing shortage of affordable housing, the effects of post-2008 financial crisis regulations on American homeownership, and the contentious issue of interest rates, on which Dimon and Trump have publicly disagreed, <a href="https://www.wsj.com/finance/jpmorgan-chase-jamie-dimon-trump-visits-01a36928?mod=hp_lead_pos3">reported</a> The Wall Street Journal.
Dimon, who has consistently supported Federal Reserve Chair&nbsp;Jerome Powell&nbsp;and the Fed&#8217;s independence, told Trump that interest rates could be lowered if the economy is strong enough. This isn't the first time Dimon has shared this perspective with Trump. The meeting occurred soon after Trump visited a construction site at the Federal Reserve — a visit that has stirred criticism of Powell among the president's supporters.
<h3 class="wp-block-heading">Dimon&#8217;s Past Warnings On Trump Tariffs, High Interest Rates</h3>
The recent meetings between Dimon and Trump come as a surprise, given their history of public disagreements and insults. The two had not had a substantial conversation for years, and their public exchanges had been acrimonious.
In May, Dimon reportedly committed to intensifying JPMorgan&#8217;s association with Chinese capital markets following a meeting with high-ranking <a href="https://www.benzinga.com/markets/25/05/45582003/jamie-dimon-who-once-said-trump-was-right-about-some-of-china-now-reportedly-appears-to-be-siding-with-xi-jinping-amid-washington-beijing-tensions">Chinese officials</a>, including Beijing's chief trade negotiator, He Lifeng. This commitment followed a recent agreement between Beijing and Washington to decrease tariffs, indicating a significant relaxation of trade tensions.
Earlier in the same month, Dimon, who had correctly<a href="https://www.benzinga.com/markets/equities/25/05/45535142/jamie-dimon-who-flagged-trouble-before-2008-lehman-brothers-collapse-now-warns-sp-earnings-could-fall-to-0rougher-time-for-markets-says-dan-niles"> predicted trouble</a> before the 2008 Lehman Brothers collapse, warned that Wall Street's expectations for S&amp;P 500 earnings growth could plummet from 12% to 0% as tariff impacts ripple through the economy.
While Dimon support&#8217;s Fed&#8217;s independence, he also warned about the potential underestimation of the risk of higher <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46361695/jamie-dimon-warns-market-may-be-underestimating-rate-hike-risks-flags-investor-complacency-amid-trump-tariffs-cause-of-concern">U.S. interest rates, </a>calling it a &#8220;cause of concern.&#8221;
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/07/46488893/at-14-jamie-dimon-owned-his-first-stock-watched-a-45-market-crash-only-to-learn-this-investment-lesson-history-does-rhyme">At 14, Jamie Dimon Owned His First Stock, Watched A 45% Market Crash Only To Learn This Investment Lesson: &#8216;History Does Rhyme&#8217; </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump, Jamie Dimon Reportedly Meet After President's Fed Visit, Ending Years-Long Rift: What Changed?

WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) reported quarterly earnings of $3.39 per share which beat the analyst consensus estimate of $3.35 by 1.22 percent. This is a 5.61 percent increase over earnings of $3.21 per share from the same period last year. The company reported quarterly sales of $5.900 billion which beat the analyst consensus estimate of $5.796 billion by 1.79 percent. This is a 7.66 percent increase over sales of $5.480 billion the same period last year.

WESCO Intl Q2 Adj. EPS $3.39 Beats $3.35 Estimate, Sales $5.900B Beat $5.796B Estimate

Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) reported quarterly earnings of $3.09 per share which beat the analyst consensus estimate of $2.98 by 3.55 percent. This is a 3.44 percent decrease over earnings of $3.20 per share from the same period last year. The company reported quarterly sales of $3.023 billion which beat the analyst consensus estimate of $2.962 billion by 2.05 percent. This is a 1.23 percent increase over sales of $2.986 billion the same period last year.

Air Products & Chemicals Q3 Adj. EPS $3.09 Beats $2.98 Estimate, Sales $3.023B Beat $2.962B Estimate

City Office REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIO#NYSE">CIO</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.27 by 2.94 percent. This is unchanged from the same period last year. The company reported quarterly sales of $42.34 million which beat the analyst consensus estimate of $42.28 million by 0.14 percent. This is a 0 percent increase over sales of $42.34 million the same period last year.

City Office REIT Q2 FFO $0.28 Beats $0.27 Estimate, Sales $42.34M Beat $42.28M Estimate

PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.36 by 13.41 percent. This is unchanged from the same period last year. The company reported quarterly sales of $5.898 billion which missed the analyst consensus estimate of $6.369 billion by 7.39 percent. This is a 1.47 percent decrease over sales of $5.986 billion the same period last year.

PG&E Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $5.898B Miss $6.369B Estimate

Cigna Group Q2 2025 Adj. EPS $7.20 Beats $7.13 Estimate, Sales $67.134B Beat $62.464B Estimate

Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) reported quarterly earnings of $2.36 per share which beat the analyst consensus estimate of $1.96 by 20.29 percent. This is a 26.2 percent increase over earnings of $1.87 per share from the same period last year. The company reported quarterly sales of $4.044 billion which missed the analyst consensus estimate of $4.660 billion by 13.22 percent. This is a 21.52 percent decrease over sales of $5.153 billion the same period last year.

Lincoln National Q2 Adj. EPS $2.36 Beats $1.96 Estimate, Sales $4.044B Miss $4.660B Estimate

Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.34 by 20.23 percent. This is a 7.89 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $135.10 million which beat the analyst consensus estimate of $128.05 million by 5.51 percent. This is a 7.54 percent increase over sales of $125.63 million the same period last year.

Comments

GrowGeneration

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL